This content is current only at the time of printing. This document was printed on 29 November 2021. A current copy is located at https://apvma.gov.au/node/27376
You are here
APVMA CEO commissions an independent review of operational performance
Chief Executive Officer of the Australian Pesticides and Veterinary Medicines Authority (APVMA), Dr Chris Parker, has commissioned an independent review of the agency’s operational performance to identify the underlying causes for delays in assessment and registration of agricultural and veterinary chemical products, permits and active constituents.
Performance reports released by the national regulator have demonstrated volatility in the APVMA’s operational performance and ability to meet legislative timeframes.
The statistics outline a trend of increasing applications over time, with work in progress increasing steadily by 50 – 80 applications per quarter over the first three quarters of 2016-17.
Dr Parker said a number of reports have been commissioned to review specific elements of the APVMA’s operational performance since the implementation of the 2014 legislative reforms.
“Considerable work has gone into improving our systems and processes at the APVMA and we’re not seeing this translate into more applications being assessed and finalised on time,” Dr Parker said.
“The performance audit completed by the Australian National Audit Office provided a view of how well the APVMA implemented the 2014 legislative reforms and gave an assessment on whether we’d achieved operational efficiencies, but this did not consider the wider impact or drivers of operational performance.
“We’ve got a unique opportunity here to look at our business more critically and build quality in our regulatory operations ahead of our relocation to Armidale.
“The review I’ve commissioned will provide an objective assessment of what we can be doing better by undertaking a root cause analysis of the drivers that influence our operational performance.
“We’re determined to improve our regulatory performance at the APVMA, and we will.”
The independent review will commence in September and be finalised by the end of 2017.